Table 1.
Baseline patient characteristics in patients receiving G-B in cohort 1 of the GREEN study (intent-to-treat population)
| Characteristic | All patients (N = 158) |
|---|---|
| Median age, years (range) | 69.0 (42–83) |
| Male/female, n (%) | 103/55 (65.2/34.8) |
| CIRS >6, n (%) | 28 (17.7) |
| CrCl <70 ml/min, n (%) | 73 (46.2) |
| CrCl <50 ml/min, n (%) | 21 (13.3) |
| CIRS >6 and CrCl <70 ml/min, n (%) | 13 (8.2) |
| Fitness, n (%) | |
| Fita | 70 (44.3) |
| Unfitb | 88 (55.7) |
| Binet stage at screening, n (%) | |
| A | 48 (30.4) |
| B | 57 (36.1) |
| C | 53 (33.5) |
| Absolute lymphocyte count, N = 155, n (%) | |
| ≥50 × 109/l | 88 (56.8) |
| Tumor bulk, N = 139, n (%) | |
| ≥5 cm | 95 (68.3) |
| Genomic aberrations, N = 146, n (%)c | |
| 17p deletion | 11 (7.5) |
| 11q deletion | 26 (17.8) |
| 12q trisomy | 26 (17.8) |
| 13q deletion | 52 (35.6) |
| Other abnormality | 6 (4.1) |
| Normal | 25 (17.1) |
| IGHV, N = 136, n (%) | |
| Unmutated | 92 (67.6) |
| Mutated | 44 (32.4) |
| ZAP70, N = 129, n (%) | |
| Positive | 82 (63.6) |
| Negative | 47 (36.4) |
| CD38, N = 129, n (%) | |
| Positive | 70 (54.3) |
| Negative | 59 (45.7) |
CIRS Cumulative Illness Rating Scale, CrCl creatinine clearance, G-B obinutuzumab plus bendamustine, IGHV immunoglobulin heavy variable chain
a CIRS ≤6 and CrCl ≥70 ml/min
b CIRS >6 and/or CrCl <70 ml/min
c According to the hierarchical model of genomic aberrations [29]